1. WHO guidelines for the treatment of malaria 2006. [
http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
]
2. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics of artemether/lumefantrine. Clin Pharmacokinet. 1999, 37: 105-125. 10.2165/00003088-199937020-00002.
3. World Health Organization: The WHO prequalification project. [
http://www.who.int/mediacentre/factsheets/fs278/en/index.html
]
4. Olliaro P, Wells TNC: The global portfolio of new antimalarial medicines under development. Clin Pharmacol & Therapeutics. 2009, 85: 584-595. 10.1038/clpt.2009.51.
5. Cousin M, Kummerer S, Lefèvre G, Marrast AC, Stein D, Weaver M, Advisory Committee Briefing Book. Coartem® (artemether/lumefantrine): Tablets for the treatment of malaria in patients with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum. NDA 22-268. 2008, [
http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4388b1-02-Novartis.pdf
]